Corcept files reply in support of dismissing Teva's US antitrust claims over Korlym
MLex Summary: Corcept and Optime filed a reply in support of dismissing Teva Pharmaceuticals’ US claims accusing them of blocking generic competition for Corcept’s branded drug Korlym, a treatment for Cushing’s...To view the full article, register now.
Already a subscriber? Click here to view full article